VB6-845 is Viventia's anti-EpCAM therapeutic designed for the systemic treatment of patients with advanced solid tumors via intravenous (IV) infusion. There are over two and a half million new cases of EpCAM-positive solid tumors diagnosed annually in the MM7. VB6-845 is a recombinant fusion protein produced in E. coli comprised of an anti-EpCAM Fab antibody fragment recombinantly fused to Viventia's proprietary de-immunized protein payload, deBouganin.
An exploratory first-in-man study was performed to evaluate the safety and tolerability of VB6-845 in patients with advanced solid tumors of epithelial origin. VB6-845 was administered as a monotherapy IV fusion, once weekly at two dose levels (1.0 and 2.0 mg/kg). In total, 13 patients were enrolled into 2 cohorts and patient data indicated that VB6-845:
- Had an excellent safety profile
- Was efficacious and well-tolerated
- Resulted in stable disease in 6 out of 13 end-stage patients
- Carried a proven non-immunogenic payload, making VB6-845 suitable for repeat systemic dosing
For more information, to download our VB6-845 Licensing Brochure